Publications

34. An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models
Schepens et al.,
Sci Transl Med (2021) doi:10.1126/ scitranslmed.abi7826:eabi7826. 		Ugent/VIB KULeuven
33. A vulnerable, membrane-proximal site in human respiratory syncytial virus F revealed by a prefusion-specific single-domain antibody
Rossey et al.,
J Virol (2021) doi:10.1128/JVI.02279-20. 		Ugent/VIB
32. Comparing infectivity and virulence of emerging SARS-CoV-2 variants in Syrian hamsters
Abdelnabi et al.,
EBioMedicine (2021) 68:103403. 		KULeuven
31. PKR activity modulation by phosphomimetic mutations of serine residues located three aminoacids upstream of double-stranded RNA binding motifs
Cesaro et al.,
Sci Rep (2021) 11:9188. 		KULeuven
30. A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.
Sanchez-Felipe et al.,.
Nature (2021) 590: 320-325. 		KULeuven
29. Identification of host factors binding to dengue and Zika virus subgenomic RNA by efficient yeast three-hybrid screens of the human ORFeome
Jansen et al.,
RNA Biol (2021) 18:732-744. 		KULeuven
28. Nucleocytoplasmic Trafficking Perturbation Induced by Picornaviruses.
Lizcano-Perret B, Michiels T.
Viruses (2021) 13. 		UCLouvain
27. Initial Step of Virus Entry: Virion Binding to Cell-Surface Glycans. Koehler, M., et al.
Annu Rev Virol (2020) 7 (1): 143-165. 		ULiege
26. Small-molecule inhibitors of TBK1 serve as an adjuvant for a plasmid-launched live-attenuated yellow fever vaccine.
Sharma, S., et al.
Hum Vaccin Immunother (2020) 16 (9): 2196-2203. 		KULeuven
25. A gammaherpesvirus licenses CD8 T cells to protect the host from pneumovirus-induced immunopathologies.
Dourcy, M., et al.
Mucosal Immunol (2020) 13 (5): 799-813. 		ULiege
24. Animal models for COVID-19.
Munoz-Fontela, C., et al.
Nature (2020) 586 (7830): 509-515. 		KULeuven
23. STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters.
Boudewijns, R., et al.
Nat Commun (2020) 11 (1): 5838. 		KULeuven
UGent/VIB
22. A dengue type 2 reporter virus assay amenable to high-throughput screening.
Li, L. H., et al.
Antiviral Res (2020) 183: 104929. 		KULeuven
21. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies.
Wrapp, D., et al.
Cell (2020) 181 (5): 1004-1015 e1015. 		UGent/VIB
20. Cell-Mediated Responses to Human Metapneumovirus Infection.
Ballegeer, M. and X. Saelens
Viruses (2020) 12 (5).		 UGent/VIB
19. Updates in Hepatitis E virus (HEV) field; lessons learned from human liver chimeric mice.
Sayed, I. M. and P. Meuleman
Rev Med Virol (2020) 30 (2): e2086. 		UGent
18. mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice.
Van Hoecke, L., et al.
Mol Ther Nucleic Acids (2020) 20: 777-787.		 UGent/VIB
17. The Development of RNA-KISS, a Mammalian Three-Hybrid Method to Detect RNA-Protein Interactions in Living Mammalian Cells.
Lemmens, I., et al.
J Proteome Res (2020) 19 (7): 2529-2538. 		UGent/VIB
KULeuven
16. Blocking entry of hepatitis B and D viruses to hepatocytes as a novel immunotherapy for treating chronic infections.
Maravelia, P., et al.
J Infect Dis (2020).		 UGent
15. Robust hepatitis E virus infection and transcriptional response in human hepatocytes.
Todt, D., et al.
Proc Natl Acad Sci U S A (2020) 117 (3): 1731-1741. .		 UGent
14. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice.
Kum, D. B., et al.
Emerg Microbes Infect (2020) 9 (1): 520-533. 		KULeuven
13. The Leader Protein of Theiler's Virus Prevents the Activation of PKR.
Borghese, F., et al.
J Virol (2019) 93 (19).		 KULeuven
12. Infectivity and stability of hepatitis C virus in different perfusion solutions.
Helfritz, F. A., et al.
Transpl Infect Dis (2019) 21 (5): e13135.		 UGent
11. Hepatitis E virus prevalence in Flemish blood donors.
Vercouter, A. S., et al.
J Viral Hepat (2019) 26 (10): 1218-1223.		 UGent
10. Animal Models for Hepatitis E virus.
Corneillie, L., et al.
Viruses (2019) 11 (6).		 UGent
09. Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis.
Sayed, I. M., et al.
J Infect Dis (2019) 220 (5): 811-819. 		UGent
08. Oral Vaccination with Replication-Competent Adenovirus in Mice Reveals Dissemination of the Viral Vaccine beyond the Gastrointestinal Tract.
Goffin, E., et al.
J Virol (2019) 93 (13). 		ULiege
07. IFN-lambda Decreases Murid Herpesvirus-4 Infection of the Olfactory Epithelium but Fails to Prevent Virus Reactivation in the Vaginal Mucosa.
Jacobs, S., et al.
Viruses (2019) 11 (8).		 UCLouvain/ULiege
06. New insights into the ORF2 capsid protein, a key player of the hepatitis E virus lifecycle.
Ankavay, M., et al.
Sci Rep (2019) 9 (1): 6243.		 UGent
05. Absence of zoonotic hepatitis E virus infection in Flemish dairy cows.
Vercouter, A. S., et al.
Int J Food Microbiol (2018) 281: 54-59.		 UGent
04. The natural compound silvestrol inhibits hepatitis E virus (HEV) replication in vitro and in vivo.
Todt, D., et al.
Antiviral Res (2018) 157: 151-158.		 UGent
03. Species Specificity of Type III Interferon Activity and Development of a Sensitive Luciferase-Based Bioassay for Quantitation of Mouse Interferon-lambda.
Jacobs, S., et al.
J Interferon Cytokine Res (2018) 38 (11): 469-479.		 UGent
02. Antiviral effect of the nucleoside analogue cidofovir in the context of sexual transmission of a gammaherpesvirus in mice.
Zeippen, C., et al.
J Antimicrob Chemother (2018) 73 (8): 2095-2103.		 ULiege
KULeuven
01. Innate Immune Detection of Cardioviruses and Viral Disruption of Interferon Signaling.
Freundt, E. C., et al.
Front Microbiol (2018) 9: 2448.		 UCLouvain